118 related articles for article (PubMed ID: 24205892)
1. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.
Mock S; Dmochowski RR
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1659-66. PubMed ID: 24205892
[TBL] [Abstract][Full Text] [Related]
2. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
3. Review of fesoterodine.
Vella M; Cardozo L
Expert Opin Drug Saf; 2011 Sep; 10(5):805-8. PubMed ID: 21639817
[TBL] [Abstract][Full Text] [Related]
4. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
Michel MC
Expert Opin Pharmacother; 2008 Jul; 9(10):1787-96. PubMed ID: 18570610
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU; Malhotra B
Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
[TBL] [Abstract][Full Text] [Related]
6. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine.
de Mey C; Mateva L; Krastev Z; Sachse R; Wood N; Malhotra B
J Clin Pharmacol; 2011 Mar; 51(3):397-405. PubMed ID: 20371737
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder.
Malhotra B; El-Tahtawy A; Wang EQ; Darekar A; Cossons N; Crook TJ; Scholfield D; Reddy P
J Pediatr Urol; 2012 Aug; 8(4):336-42. PubMed ID: 22417681
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
Sun F; Sui C; Zhou Y; Liu X; Shi Y; Wu Y; Li Y
Int J Pharm; 2013 Sep; 454(1):532-8. PubMed ID: 23891744
[TBL] [Abstract][Full Text] [Related]
9. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
10. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Malhotra B; Gandelman K; Sachse R; Wood N; Michel MC
Curr Med Chem; 2009; 16(33):4481-9. PubMed ID: 19835561
[TBL] [Abstract][Full Text] [Related]
11. Tolterodine for the treatment of overactive bladder.
Salvatore S; Serati M; Bolis P
Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.
Kraus SR; Ruiz-Cerdá JL; Martire D; Wang JT; Wagg AS
Urology; 2010 Dec; 76(6):1350-7. PubMed ID: 20974482
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.
Van Kerrebroeck PE; Heesakkers J; Berriman S; Padmanabhan Aiyer L; Carlsson M; Guan Z
Int J Clin Pract; 2010 Apr; 64(5):584-93. PubMed ID: 20201992
[TBL] [Abstract][Full Text] [Related]
14. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
15. Fesoterodine: Pharmacological properties and clinical implications.
Gamé X; Peyronnet B; Cornu JN
Eur J Pharmacol; 2018 Aug; 833():155-157. PubMed ID: 29803689
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological profile and clinical findings of fesoterodine (Toviaz®Tablets )].
Hizue M; Ochi Y; Imura M; Yamagami H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):203-13. PubMed ID: 24717610
[No Abstract] [Full Text] [Related]
17. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
19. Early onset of fesoterodine efficacy in subjects with overactive bladder.
Goldman HB; Morrow JD; Gong J; Tseng LJ; Schneider T
BJU Int; 2011 Feb; 107(4):598-602. PubMed ID: 20868387
[TBL] [Abstract][Full Text] [Related]
20. Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians.
Trocio JN; Brubaker L; Schabert VF; Bavendam T; Chen CI; Zou KH; Petrilla AA; Burgio KL
Postgrad Med; 2014 May; 126(3):246-56. PubMed ID: 24918809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
